Loading the section…
The price of Beam Therapeutics Inc. (BEAM) on October 9, 2026 is 25.70 USD, +4.47% on the day. Over 52 weeks the stock traded between 20.23 USD and 38.26 USD; the price now sits 30% of the way up that range. Over the past year the price changed by -4.81%. Market capitalization is 2.64 billion USD, rank 26 among 128 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): +1.22 %
Beam Therapeutics Inc. trades on Nasdaq under the ticker BEAM. The company belongs to the Health care sector. The trading history on this page starts on 6 February 2020.
Over the past 52 weeks BEAM has traded between 20.23 $ and 38.26 $. As of 9 October 2026 the price stood 30.34 % of the way from the 52-week low to the high.
Over one year BEAM shares fell 4.81 %; over six months they fell 6.31 %. Volatility over 90 days is 64.68 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 16.1, above the sector median of 4.0. Price to book is 2.3, below the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 24.72 | 26.23 | 24.55 | 25.70 | 2M |
| 8 October 2026 | 24.26 | 24.69 | 23.91 | 24.60 | 2M |
| 7 October 2026 | 24.64 | 25.37 | 24.45 | 24.77 | 2M |
| 6 October 2026 | 26.80 | 26.94 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Beam Therapeutics Inc. (BEAM) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 164.0m $, net income was -65.0m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139, US
Beam Therapeutics Inc. reported revenue of 164M $ and a net loss of 65M $ over the last four quarters. Net margin is −39.66 %. Revenue changed by +157.97 % year over year. Earnings per share are −0.48 $. Market capitalisation is 2.6B $.
BEAM has a return on equity of −5.59 %, above the sector median of −41.68 %. Return on assets is −4.39 %, above the sector median of −32.11 %. Operating margin is −226.58 %, below the sector median of −26.84 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 110.42 | +0.53 % | 253M |
| BIIBBiogen Inc. | 225.71 | +3.33 % | 227M |
| KODKodiak Sciences Inc | 99.87 | +5.95 % | 219M |
| 24.87 |
| 25.23 |
| 3M |
| 5 October 2026 | 24.48 | 26.04 | 23.83 | 25.67 | 2M |
| 2 October 2026 | 25.00 | 25.48 | 24.21 | 24.50 | 1M |
| 1 October 2026 | 24.24 | 24.98 | 23.96 | 24.39 | 2M |
| 30 September 2026 | 24.79 | 25.20 | 24.41 | 24.45 | 2M |
| 29 September 2026 | 23.88 | 24.76 | 23.88 | 24.52 | 2M |
| 28 September 2026 | 24.02 | 24.66 | 23.44 | 24.23 | 1M |
| 25 September 2026 | 24.97 | 24.97 | 23.75 | 24.27 | 1M |
| 24 September 2026 | 23.88 | 24.81 | 23.16 | 24.66 | 2M |
| 23 September 2026 | 25.75 | 26.24 | 24.22 | 24.37 | 2M |
| 22 September 2026 | 25.62 | 26.50 | 25.07 | 25.93 | 2M |
| 21 September 2026 | 25.45 | 25.66 | 24.83 | 25.26 | 2M |
| 18 September 2026 | 24.92 | 25.18 | 24.26 | 24.95 | 2M |
| 17 September 2026 | 24.28 | 25.50 | 24.05 | 24.67 | 2M |
| 16 September 2026 | 23.41 | 23.65 | 22.67 | 23.10 | 2M |
| 15 September 2026 | 23.82 | 23.84 | 22.86 | 23.22 | 3M |
| 14 September 2026 | 24.02 | 24.93 | 23.99 | 24.12 | 1M |